A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy.

• Váldodahkkit: Smriti Mondal (Dahkki), Pradyot Bhattacharya (Dahkki), Mehebubar Rahaman (Dahkki), Nahid Ali (Dahkki), Rama Prosad Goswami (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Public Library of Science (PLoS), 2010-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

BACKGROUND: The present pilot study investigating the minimum dose for short-course single and double-dose treatment of kala-azar with an apparently new liposomal formulation of amphotericin B, Fungisome, led to identification of immunological components for early detection of success and/or failure...